CD8A and melanoma: Conversely, SOCS1-silencing favors an anti-melanoma immune response by activation of effector T-CD8+ cells against the tumor, concomitant with regulation of ERK1/2 and p38 MAPK pathways and decreased expression of PD-L1 in murine melanoma B16F10-Nex2 cells.